Highlights

  • Third quarter total Revenue rose 36% to USD 12.1 million.
  • Gross profit was USD 7.1 million against USD 5.6 million.
  • The net loss was USD 7.5 million, or USD 0.24 per share.
  • Cash and cash equivalents were USD 46.2 million at quarter end.

ClearPoint Neuro, Inc. (NASDAQ:CLPT) shares were trading near their 52-week low at USD 8.57 on November 6, 2026, down 1.38% on the day. The company reported third quarter total revenue of USD 12.1 million against USD 8.9 million, a 36% increase, and a net loss of USD 7.5 million against USD 5.9 million.

ClearPoint has a market Capitalization of about USD 274.71 million at the current price. It had 32,054,268 shares of common stock outstanding as of October 21, 2026.

Third Quarter Results

Gross profit was USD 7.1 million against USD 5.6 million. The operating loss was USD 6.3 million against USD 5.3 million. Research and Development costs were USD 4 million against USD 3.5 million, and general and administrative expenses were USD 3.8 million, an increase of USD 0.3 million, or 7%. Loss per share was USD 0.24 against USD 0.21.

Nine Month Results

Total revenue was USD 35.1 million against USD 26.6 million, and Gross Profit was USD 21.5 million against USD 16.3 million. The operating loss was USD 25.1 million against USD 17.1 million, and the net loss was USD 28.3 million against USD 17.8 million, or USD 0.94 per share against USD 0.63. Net cash used in Operating Activities was USD 20.1 million against USD 11.8 million. The accumulated Deficit was USD 245.3 million.

Management Commentary

Management said it supports more than 60 active biopharma partners that continue to announce data readouts and global clinical trial initiations, including multiple Phase III studies that are enrolling or expected to start in 2027. It said capital sales results in the third quarter and its capital sales funnel for the fourth quarter and 2027 show new sites choosing the ClearPoint platform. Management estimated revenue of between USD 13,000 and USD 20,000 per procedure from the laser, accessories and software used.

Balance Sheet and Financing

The company accessed its existing at the market Facility for the first time in the third quarter and ended the quarter with USD 46.2 million in cash and cash equivalents against USD 45.9 million at the end of 2025. Total Assets were USD 112.7 million, total liabilities were USD 85.5 million and stockholders' Equity was USD 27.3 million.